Marquette University

TAMPA, Fla., Sept. 12, 2024 /PRNewswire/ -- Probo Medical ("Probo"), a global diagnostic imaging solutions provider, has announced the appointment of Michael Asmer as Chairman of the Board and Greg Kopulos as Chief Executive Officer of Probo. Michael Asmer was formerly Chief Executive Officer of Probo and, prior to Probo, was the founder and Chief Executive Officer of MedCorp, which was acquired by Probo in 2018. Prior to MedCorp, Asmer held various leadership roles at Physician Sales and Service (PSS), prior to its acquisition by McKesson, and also at Henry Schein. Asmer earned his Bachelor's degree from the University of South Carolina. "I am tremendously proud of what our team has accomplished over the last five years at Probo and am also excited for what lies ahead," stated Asmer. "With the integration of recent acquisitions, Probo enters a new phase of growth where we can support our customers with a comprehensive offering of diagnostic imaging solutions." Greg Kopulos joined Probo in 2024 from Chartis, a healthcare consulting firm where he was President of their Clinical Quality Solutions business. Prior to that, he spent 20 years at GE Healthcare where among other roles, he was Chief Operating Officer of Global Service, Chief Operating Officer of US & Canada as well as the Senior Vice President of Strategy. Kopulos earned his Masters of Business Administration from Marquette University and his Bachelor's degree from University of Wisconsin-Whitewater. "Probo is well on its way to becoming a global leader in diagnostic imaging solutions. I am humbled and excited to build on the great work of Michael and the entire Probo team," remarked Kopulos. "With the continued investment in and integration of our prior acquisitions, Probo has never been better positioned to help our customers deliver quality care to their patients while providing needed cost savings." Probo Medical is backed by Avista Healthcare Partners, a leading private equity firm focused exclusively on healthcare with over $8 billion invested in more than 45 growth-oriented healthcare businesses globally. About Probo Medical Probo Medical is a global diversified solutions provider of diagnostic imaging products and services, including equipment sales, service, rental, repair and installation. For more information about Probo Medical, visit . Contacts For Probo Medical: Contact: Adam Walter, Probo Medical Email: [email protected] For Avista Healthcare Partners: Daniel Yunger / William Halliday Kekst CNC [email protected] / [email protected] SOURCE Probo Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN--( BUSINESS WIRE )--The "Orthodontic Materials and Products Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering. The report provides extensive coverage of Orthodontic Materials and Products under development. It reviews details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities. The report also reviews the major players involved in the development of Orthodontic Materials and Products and lists all their pipeline projects. It covers pipeline products based on various stages of development, ranging from Early Development to Approved/Issued stage. Furthermore, the report provides key clinical trial data of ongoing trials specific to pipeline products in the Orthodontic Materials and Products segment. It also highlights recent developments in the industry related to orthodontic materials and products. Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Orthodontic Materials and Products under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date A selection of companies mentioned in this report includes Align Technology Inc Augusta University Banaras Hindu University Boston Children's Hospital ClearCorrect LLC Covalon Technologies Ltd envisionTEC GmbH Harvard University Heinrich-Heine University King Abdullah University of Science and Technology King's College London Marquette University Propel Orthodontics, LLC Rutgers The State University of New Jersey SandBox Dental Labs Inc Tianjin ZhengLi Technology Co Ltd University of Michigan Pediatric Device Consortium University of Minnesota Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Orthodontic Materials and Products Overview 3 Products under Development 3.1 Orthodontic Materials and Products - Pipeline Products by Stage of Development 3.2 Orthodontic Materials and Products - Pipeline Products by Segment 3.3 Orthodontic Materials and Products - Pipeline Products by Territory 3.4 Orthodontic Materials and Products - Pipeline Products by Regulatory Path 3.5 Orthodontic Materials and Products - Pipeline Products by Estimated Approval Date 3.6 Orthodontic Materials and Products - Ongoing Clinical Trials 4 Orthodontic Materials and Products - Pipeline Products under Development by Companies 4.1 Orthodontic Materials and Products Companies - Pipeline Products by Stage of Development 4.2 Orthodontic Materials and Products - Pipeline Products by Stage of Development 5 Orthodontic Materials and Products Companies and Product Overview 6 Orthodontic Materials and Products- Recent Developments 7 Appendix For more information about this report visit https://www.researchandmarkets.com/r/tc6ke2 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

MONDAY, April 24, 2023 -- When exercise studies are led by men, female participants are often in short supply. While this underrepresentation of female research subjects has been documented in everything from clinical trials to cell cultures, a new study links researchers' gender and women’s participation. “Our findings provide direct evidence of the link between gender of authors and gender of research participants,” said lead study author Jessica Linde , a doctoral candidate at Marquette University in Milwaukee. Having too few women participating results in gaps in understanding how certain interventions work in females. For this study, researchers analyzed 971 original research articles in three major journals that focus on exercise physiology, zeroing in on studies published in 1991 and in 2021. They found that in 1991, 51% of the papers were written by all-male teams. That was also true of about 18% of papers in 2021. All female-research teams also declined over the period, from 1.8% in 1991 to 1.1% in 2021. While the number of women participating in exercise studies rose over the years, they represented just one-third of study participants in 2021. The number of female participants was lower in both years when the study leader (or last author) was a man. In 2021, Linde said, when studies were led by a woman, they included equal numbers of men and women as participants. More women in other leadership roles such as editorial board members also correlated to greater gender parity of research subjects, the study found. The findings were presented this week at a meeting of the American Physiological Society, in Long Beach, Calif. “The low representation of women as participants in exercise science and physiology research could be resolved by encouraging authors who are men to research equitable numbers of each gender,” the authors said in a meeting news release. Research presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Sources American Physiological Society, news release, April 21, 2023 Posted April 2023